



THE JOURNAL OF CLINICAL PSYCHIATRY

Supplementary Material

Article Title: Pharmacogenomic Associations With Weight Gain in Olanzapine Treatment of Patients Without Schizophrenia

Author(s): John P. Houston, MD, PhD; Jared Kohler, PhD; Jeffrey R. Bishop, PharmD; Vicki L. Ellingrod, PharmD; Katherine M. Ostbye, MPH; Fangyi Zhao, PhD; Robert R. Conley, MD; Vicki Poole Hoffmann, PharmD; and Bonnie A. Fijal, PhD

DOI Number: 10.4088/JCP.11m06916

List of Supplementary Material for the article

1. [eTable 1](#) Basic Demographics for the Olanzapine Cohorts And All Subjects Who Received Olanzapine Treatment

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary Material

eTable 1. Basic Demographics for the Olanzapine Genetic Cohorts and All Subjects Who Received Olanzapine Treatment^a

Variable	Olanzapine Overall					Olanzapine Genetic				
	Study A 2.5 mg	Study A 5-10 mg	Study B	Study C	Study D	Study A 2.5 mg	Study A 5-10 mg	Study B	Study C	Study D
Number of Patients	150	148	155	201	199	52	44	70	139	73
Age, mean ± SD	32.6 ± 11.2	32.9 ± 10.0	31.8 ± 9.4	39.5 ± 12.0	44.3 ± 10.8	33.3 ± 11.9	33.4 ± 10.1	32.6 ± 8.9	38.2 ± 12.0	43.4 ± 9.8
Sex, Female, n (%)	109 (72.7%)	106 (71.6%)	113 (72.9%)	109 (54.2%)	123 (61.8%)	41 (78.8%)	29 (65.9%)	49 (70%)	70 (50.4%)	44 (60.3%)
Ethnicity, %										
Caucasian	68%	58.8%	87.7%	79.6%	92.4%	59.6%	40.9%	87.1%	80.6%	76.7%
African	4.7%	7.4%	6.5%	13.9%	9.5%	5.8%	13.6%	5.7%	13.7%	9.6%
Hispanic	24%	30.4%	1.3%	5%	6%	28.8%	45.5%	0%	5.8%	8.2%
East/Southeast Asian	0.7%	2.7%	1.3%	0.5%	0.5%	0%	0%	1.4%	0%	1.4%
Western Asian	0.7%	0%	0.6%	0%	0%	0%	0%	4.3%	0%	0%
Other	2%	0.7%	2.6%	0%	1.5%	5.8%	0%	1.4%	0%	4.1%
Country, % US (n/total)	56.0% (84/150)	60.8% (90/148)	25.2% (39/155)	59.2% (119/201)	N/A	73.1% (38/52)	68.2% (30/44)	38.6% (27/70)	71.2% (99/139)	87.7% (64/73)
Baseline weight (kg), mean ± SD	70.8 ± 18.7	71.4 ± 18.4	71.5 ± 19.2	82.5 ± 21.6	86.2 ± 21.9	75.4 ± 20.3	78.7 ± 17.4	78.8 ± 24.2	82.0 ± 23.3	88.5 ± 21.6
Baseline BMI (kg/m ²), mean ± SD	N/A	N/A	N/A	28.2 ± 7.3	30.4 ± 7.1	27.3 ± 6.0	27.4 ± 4.6	27.08 ± 6.5	28.2 ± 7.7	31.1 ± 6.4
Mean weight change (kg)	2.1	3.2	2.9	1.3	5.53	1.57	2.76	2.45	2.3	4.7
Rate of 7% weight increase, %	20.3%	30.6%	34.2%	22.9	22.2%	17.3%	31.8%	27.1%	20.9%	15.1%
OLZ dose (mg), mean ± SD	2.5	6.66 ± 2.91	7.1 ± 5.1	11.4 ± 5.0	8.1 ± 3.5	2.97 ± 1.17	5.6 ± 2.02	6.7 ± 4.49	12.4 ± 3.8	7.6 ± 3.04
OLZ dose over 8 weeks (mg), mean ± SD	N/A	N/A	N/A	N/A	N/A	2.4 ± 0.34	5.5 ± 1.7	6.5 ± 4.1	12.6 ± 3.7	7.6 ± 3.0

Abbreviations: BMI = body mass index; n = number; N/A = not applicable; OLZ = olanzapine; SD = standard deviation; US = United States.

^a Patient diagnoses: Study A and B, Borderline Personality Disorder; Study C, Mania, Bipolar I Disorder; Study D, Treatment-Resistant Major Depressive Disorder.